Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Philip Stephens; Chris Hunter; Graham Bignell; Sarah Edkins; Helen Davies; Jon Teague; Claire Stevens; Sarah O'Meara; Raffaella Smith; Adrian Parker; Andy Barthorpe; Matthew Blow; Lisa Brackenbury; Adam Butler; Oliver Clarke; Jennifer Cole; E. Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca Foster; Kristian Gray; Chris Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S. Cooper; Adrienne M. Flanagan; Margaret Knowles; Suet Y. Leung; David N. Louis; Leendert H.J. Looijenga; Bruce Malkowicz; Marco A. Pierotti; Bin Teh; Georgia Chenevix-Trench; Barbara L. Weber; Siu T. Yuen; Grace Harris; Peter Goldstraw; Andrew G. Nicholson; P. Andrew Futreal; Richard Wooster; Michael R. Stratton

Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Philip Stephens, Chris Hunter, Graham Bignell, Sarah Edkins, Helen Davies, Jon Teague, Claire Stevens, Sarah O'Meara, Raffaella Smith, Adrian Parker, Andy Barthorpe, Matthew Blow, Lisa Brackenbury, Adam Butler, Oliver Clarke, Jennifer Cole, E. Dicks, Angus Dike, Anja Drozd, Ken EdwardsSimon Forbes, Rebecca Foster, Kristian Gray, Chris Greenman, Kelly Halliday, Katy Hills, Vivienne Kosmidou, Richard Lugg, Andy Menzies, Janet Perry, Robert Petty, Keiran Raine, Lewis Ratford, Rebecca Shepherd, Alexandra Small, Yvonne Stephens, Calli Tofts, Jennifer Varian, Sofie West, Sara Widaa, Andrew Yates, Francis Brasseur, Colin S. Cooper, Adrienne M. Flanagan, Margaret Knowles, Suet Y. Leung, David N. Louis, Leendert H.J. Looijenga, Bruce Malkowicz, Marco A. Pierotti, Bin Teh, Georgia Chenevix-Trench, Barbara L. Weber, Siu T. Yuen, Grace Harris, Peter Goldstraw, Andrew G. Nicholson, P. Andrew Futreal, Richard Wooster, Michael R. Stratton

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

702 Citaten (Scopus)

Samenvatting

The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

Originele taal-2	Engels
Pagina's (van-tot)	525-526
Aantal pagina's	2
Tijdschrift	Nature
Volume	431
Nummer van het tijdschrift	7008
Status	Gepubliceerd - 2004
Extern gepubliceerd	Ja

Citeer dit

@article{ca633b4b92984de4b9825981d0a913be,

title = "Lung cancer: intragenic ERBB2 kinase mutations in tumours.",

abstract = "The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4\% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10\% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.",

author = "Philip Stephens and Chris Hunter and Graham Bignell and Sarah Edkins and Helen Davies and Jon Teague and Claire Stevens and Sarah O'Meara and Raffaella Smith and Adrian Parker and Andy Barthorpe and Matthew Blow and Lisa Brackenbury and Adam Butler and Oliver Clarke and Jennifer Cole and E. Dicks and Angus Dike and Anja Drozd and Ken Edwards and Simon Forbes and Rebecca Foster and Kristian Gray and Chris Greenman and Kelly Halliday and Katy Hills and Vivienne Kosmidou and Richard Lugg and Andy Menzies and Janet Perry and Robert Petty and Keiran Raine and Lewis Ratford and Rebecca Shepherd and Alexandra Small and Yvonne Stephens and Calli Tofts and Jennifer Varian and Sofie West and Sara Widaa and Andrew Yates and Francis Brasseur and Cooper, \{Colin S.\} and Flanagan, \{Adrienne M.\} and Margaret Knowles and Leung, \{Suet Y.\} and Louis, \{David N.\} and Looijenga, \{Leendert H.J.\} and Bruce Malkowicz and Pierotti, \{Marco A.\} and Bin Teh and Georgia Chenevix-Trench and Weber, \{Barbara L.\} and Yuen, \{Siu T.\} and Grace Harris and Peter Goldstraw and Nicholson, \{Andrew G.\} and Futreal, \{P. Andrew\} and Richard Wooster and Stratton, \{Michael R.\}",

year = "2004",

language = "English",

volume = "431",

pages = "525--526",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Research",

number = "7008",

}

Stephens, P, Hunter, C, Bignell, G, Edkins, S, Davies, H, Teague, J, Stevens, C, O'Meara, S, Smith, R, Parker, A, Barthorpe, A, Blow, M, Brackenbury, L, Butler, A, Clarke, O, Cole, J, Dicks, E, Dike, A, Drozd, A, Edwards, K, Forbes, S, Foster, R, Gray, K, Greenman, C, Halliday, K, Hills, K, Kosmidou, V, Lugg, R, Menzies, A, Perry, J, Petty, R, Raine, K, Ratford, L, Shepherd, R, Small, A, Stephens, Y, Tofts, C, Varian, J, West, S, Widaa, S, Yates, A, Brasseur, F, Cooper, CS, Flanagan, AM, Knowles, M, Leung, SY, Louis, DN, Looijenga, LHJ, Malkowicz, B, Pierotti, MA, Teh, B, Chenevix-Trench, G, Weber, BL, Yuen, ST, Harris, G, Goldstraw, P, Nicholson, AG, Futreal, PA, Wooster, R & Stratton, MR 2004, 'Lung cancer: intragenic ERBB2 kinase mutations in tumours.', Nature, vol. 431, nr. 7008, blz. 525-526.

TY - JOUR

T1 - Lung cancer

T2 - intragenic ERBB2 kinase mutations in tumours.

AU - Stephens, Philip

AU - Hunter, Chris

AU - Bignell, Graham

AU - Edkins, Sarah

AU - Davies, Helen

AU - Teague, Jon

AU - Stevens, Claire

AU - O'Meara, Sarah

AU - Smith, Raffaella

AU - Parker, Adrian

AU - Barthorpe, Andy

AU - Blow, Matthew

AU - Brackenbury, Lisa

AU - Butler, Adam

AU - Clarke, Oliver

AU - Cole, Jennifer

AU - Dicks, E.

AU - Dike, Angus

AU - Drozd, Anja

AU - Edwards, Ken

AU - Forbes, Simon

AU - Foster, Rebecca

AU - Gray, Kristian

AU - Greenman, Chris

AU - Halliday, Kelly

AU - Hills, Katy

AU - Kosmidou, Vivienne

AU - Lugg, Richard

AU - Menzies, Andy

AU - Perry, Janet

AU - Petty, Robert

AU - Raine, Keiran

AU - Ratford, Lewis

AU - Shepherd, Rebecca

AU - Small, Alexandra

AU - Stephens, Yvonne

AU - Tofts, Calli

AU - Varian, Jennifer

AU - West, Sofie

AU - Widaa, Sara

AU - Yates, Andrew

AU - Brasseur, Francis

AU - Cooper, Colin S.

AU - Flanagan, Adrienne M.

AU - Knowles, Margaret

AU - Leung, Suet Y.

AU - Louis, David N.

AU - Looijenga, Leendert H.J.

AU - Malkowicz, Bruce

AU - Pierotti, Marco A.

AU - Teh, Bin

AU - Chenevix-Trench, Georgia

AU - Weber, Barbara L.

AU - Yuen, Siu T.

AU - Harris, Grace

AU - Goldstraw, Peter

AU - Nicholson, Andrew G.

AU - Futreal, P. Andrew

AU - Wooster, Richard

AU - Stratton, Michael R.

PY - 2004

Y1 - 2004

N2 - The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

AB - The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

UR - https://www.scopus.com/pages/publications/4944232647

M3 - Article

C2 - 15457249

AN - SCOPUS:4944232647

SN - 0028-0836

VL - 431

SP - 525

EP - 526

JO - Nature

JF - Nature

IS - 7008

ER -

Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Samenvatting

Vingerafdruk

Citeer dit